Načítá se...
Immune checkpoint inhibitors for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide, and advanced HCC generally caries a poor prognosis. The treatment of advanced disease is limited to sorafenib, which provides only a limited improvement in survival, and novel therapies are, thus, sorely needed. Among emer...
Uloženo v:
| Vydáno v: | Hepat Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Future Medicine Ltd
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095178/ https://ncbi.nlm.nih.gov/pubmed/30191042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2016-0004 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|